Bayer Bought Monsanto. Now It Owns Your Food Supply.

The consolidation of the global agricultural inputs industry did not happen by accident. It happened through a sequence of mergers, patent acquisitions, and regulatory approvals that unfolded over roughly 20 years, largely out of public view. The result is a market structure in which four companies — Bayer (incorporating Monsanto), Corteva (incorporating DuPont Pioneer and Dow AgroSciences), ChemChina/Syngenta, and BASF — control approximately 60% of the global seed market and an even larger share of the agrochemical market. In the United States, the concentration is more extreme: Bayer and Corteva alone account for the majority of commercial seed sales for corn, soybeans, and cotton — the three crops that dominate American farmland.

This is not a normal market. Seeds are not widgets. They are the foundational input of agricultural production. Control of the seed supply is, at a systemic level, control of food production.

How the Consolidation Happened

The consolidation wave began in earnest in the 1990s with the commercialization of genetically modified crops. Monsanto, which had been primarily a chemical company (maker of Roundup herbicide and, earlier, Agent Orange and PCBs), pivoted aggressively into agricultural biotechnology. Its core product was Roundup Ready crops — soybeans, corn, and cotton genetically modified to survive direct application of glyphosate, Monsanto's herbicide. Farmers could spray the entire field; the weeds died; the crops survived. The logic was compelling.

The business model behind Roundup Ready was more significant than the technology. Monsanto patented the modified seed genetics and required farmers to sign licensing agreements prohibiting them from saving seeds for replanting — a practice as old as agriculture itself. Every growing season, farmers were required to purchase new Roundup Ready seeds from Monsanto. The seeds became a subscription product. And because Roundup Ready crops spread rapidly across American farmland through their economic advantages, the subscription became effectively mandatory for competitive commodity farmers.

By the mid-2000s, Monsanto had used its patent position and aggressive licensing enforcement to become the dominant supplier of soybean and corn germplasm in the United States. It had also acquired dozens of independent seed companies — Pioneer Hi-Bred, DeKalb, Asgrow, Holden's Foundation Seeds — systematically eliminating the independent seed market that had previously given farmers alternatives.

The next wave of consolidation happened between 2015 and 2018, when the industry underwent four simultaneous mega-mergers: Dow and DuPont ($130 billion); ChemChina and Syngenta ($43 billion); Bayer and Monsanto ($63 billion); and BASF's acquisition of the divested assets from the other mergers. Regulators in the United States, European Union, and China approved all four transactions with conditions — mostly requiring the sale of specific overlapping product lines. The structural result was consolidation from six major companies to four.

What Seed Patents Actually Mean for Farmers

The patent-based seed business model has transformed the farmer's relationship to their own land in ways that are rarely discussed outside agricultural communities.

When a farmer purchases Roundup Ready 2 soybeans from Bayer, they are not purchasing soybeans. They are purchasing a limited license to grow soybeans once, from seeds that contain patented genetic modifications, under terms that prohibit saving, replanting, or transferring seeds to neighbors. The farmer owns the harvested crop. They do not own the genetics that produced it.

Monsanto (now Bayer) built an enforcement infrastructure to police these licensing terms. It employed a network of investigators and maintained a tip line for reporting license violations — farmers turning in neighbors for seed saving. Between 1997 and 2010, Monsanto filed 144 lawsuits against farmers for patent infringement, settling most but pursuing others to verdict. The Supreme Court unanimously ruled in Monsanto's favor in Bowman v. Monsanto (2013), establishing that patent exhaustion did not apply to self-replicating technologies — farmers who replanted saved seeds from Roundup Ready plants were infringing Monsanto's patent.

The financial consequence for farmers is measurable. Seed prices for corn and soybeans increased approximately 300% between 1996 and 2014, far outpacing inflation and farm income growth. Input costs now represent the largest single expense category for row-crop farmers, exceeding land costs in many regions. The margin compression has contributed directly to the decline of the independent family farm and the consolidation of American agriculture into larger and larger operations — a consolidation that itself benefits the input companies, which prefer fewer, larger customers with whom they can negotiate volume pricing while maintaining aggregate pricing power.

The Glyphosate Problem

Roundup — glyphosate — was Monsanto's foundational herbicide product. The entire Roundup Ready seed system was designed to drive glyphosate sales: buy the seeds, buy the chemical. The relationship was symbiotic in Monsanto's favor.

In 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate as a "probable human carcinogen." The classification triggered tens of thousands of lawsuits from farmers, agricultural workers, and others claiming Roundup had caused their non-Hodgkin lymphoma. Bayer, which inherited the liability along with the acquisition, has paid approximately $11 billion to settle approximately 100,000 cases.

Meanwhile, glyphosate-resistant "superweeds" have developed in millions of acres of American farmland — an evolutionary consequence entirely predictable from basic biology. The industry's response has been to develop new herbicide-tolerant crops engineered to survive more toxic herbicide combinations, including 2,4-D (a component of Agent Orange) and dicamba. These new crops require new herbicide products sold by the same companies. The cycle of chemical dependency deepens.

The Regulatory Capture Dimension

The USDA, the EPA, and the FDA share oversight of agricultural biotechnology in the United States under a framework established in 1986. The framework has been repeatedly criticized for its reliance on industry-submitted safety data, its limited independent testing requirements, and its revolving-door staffing.

The approval process for Roundup Ready crops in the 1990s relied primarily on safety data submitted by Monsanto. Independent long-term studies on glyphosate's health effects were limited. The USDA's process for deregulating new biotech crops — making them freely commercializable — does not require pre-market approval; it requires only notification for crops that meet certain criteria. The regulatory framework treats agricultural biotechnology as presumptively safe unless evidence of harm is presented.

Bayer, Corteva, ChemChina/Syngenta, and BASF collectively spend tens of millions of dollars annually on lobbying in Washington and Brussels. They fund university agricultural research programs, shaping the academic literature on which regulatory agencies rely. They have placed executives and attorneys in senior positions at the USDA, EPA, and FDA. The regulatory framework that governs their products was largely designed with their participation.

What Consolidation Costs

The economic effects of agricultural input consolidation fall almost entirely on farmers and, ultimately, consumers. Seed price inflation drives down farm margins. Herbicide-resistant weeds force increased chemical use. The elimination of independent seed companies eliminates competitive alternatives. Farmers in regions with limited access to alternative seed suppliers — which is increasingly most regions — have little negotiating leverage with companies that control the patents on commercially viable genetics.

The public health effects of the glyphosate settlement wave remain contested but are not negligible. The environmental effects of herbicide-resistant weed development are ongoing and well-documented. The erosion of seed diversity — the replacement of thousands of regional seed varieties with a narrow genetic base optimized for industrial production — creates systemic agricultural fragility that does not appear on any company's balance sheet.

Bayer did not buy Monsanto to feed the world. It bought Monsanto to own the intellectual property that underlies food production. The merger created a company with unprecedented control over the foundational inputs of global agriculture. The press release said otherwise. The balance sheet tells the truth.